A discovery about the mechanisms that enable the immune system to sustain long-term protection could revolutionize treatment for chronic disease and cancer.

BMS inherited the option on PRX005 as part of its 2019 acquisition of Celgene, which signed an agreement with Dublin-based Prothena on the antibody ... in our webinar sponsored by Syneos Health ...

With over 211 antibody-drug conjugate clinical trials breaking ground so far throughout 2022, a plethora of positive clinical results, expansion of antibody-drug conjugates to novel indications ...